Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D boosted its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 10.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,013 shares of the biopharmaceutical company’s stock after purchasing an additional 6,559 shares during the period. State of New Jersey Common Pension Fund D owned about 0.11% of Xenon Pharmaceuticals worth $3,271,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its position in Xenon Pharmaceuticals by 98.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,651 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 818 shares during the period. Exchange Traded Concepts LLC lifted its position in Xenon Pharmaceuticals by 22.2% in the third quarter. Exchange Traded Concepts LLC now owns 3,967 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 720 shares during the period. Assetmark Inc. lifted its position in Xenon Pharmaceuticals by 21.5% in the third quarter. Assetmark Inc. now owns 7,103 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 1,258 shares during the period. Moody Aldrich Partners LLC acquired a new stake in Xenon Pharmaceuticals in the third quarter valued at about $312,000. Finally, Barclays PLC lifted its position in Xenon Pharmaceuticals by 3.7% in the third quarter. Barclays PLC now owns 9,521 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 342 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Performance

Shares of NASDAQ XENE opened at $40.50 on Friday. The firm’s 50 day moving average price is $43.95 and its 200 day moving average price is $41.04. Xenon Pharmaceuticals Inc. has a 1 year low of $27.99 and a 1 year high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.12. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.57) earnings per share. On average, equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

XENE has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Xenon Pharmaceuticals in a report on Wednesday, April 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $62.00 target price on shares of Xenon Pharmaceuticals in a report on Friday, April 12th. Wedbush increased their target price on shares of Xenon Pharmaceuticals from $46.00 to $51.00 and gave the company an “outperform” rating in a report on Friday, March 1st. Bank of America increased their target price on shares of Xenon Pharmaceuticals from $52.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. Finally, Citigroup initiated coverage on shares of Xenon Pharmaceuticals in a report on Thursday, January 4th. They issued a “buy” rating and a $62.00 target price for the company. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $59.44.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Steven Gannon sold 13,000 shares of Xenon Pharmaceuticals stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total value of $601,640.00. Following the transaction, the director now owns 2,000 shares in the company, valued at approximately $92,560. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, EVP Sherrington Robin sold 7,137 shares of Xenon Pharmaceuticals stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total transaction of $330,300.36. Following the transaction, the executive vice president now owns 8,398 shares in the company, valued at approximately $388,659.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steven Gannon sold 13,000 shares of Xenon Pharmaceuticals stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total transaction of $601,640.00. Following the transaction, the director now owns 2,000 shares in the company, valued at approximately $92,560. The disclosure for this sale can be found here. 5.43% of the stock is owned by company insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.